2025-11-11T13:05:26-06:00 2024-12-31 333709623 COHNREZNICK ADVISORY LLC 7501 WISCONSIN AVENUE SUITE 400E BETHESDA MD 20814 990 2024-01-01 136180380 AMERICAN SOCIETY OF CLINICAL ONCOLOGY INC AMER 5714831300 2318 MILL ROAD 800 ALEXANDRIA VA 22314 MELINDA O'LEARY CFO 5714831300 2025-11-07 1 1 ZACHARY SEGAL P01511850 3016529100 2025-10-23 2024 2025-03-06 01:10:19Z ASCO CLIFFORD HUDIS MD CEO 2318 MILL ROAD 800 ALEXANDRIA VA 22314 177189397 0 X WWW.ASCO.ORG X 1965 NY SEE SCHEDULE O:ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY PATIENT CARE. 18 18 488 5127 14268653 7667167 16259283 7681674 127986242 137635933 23661513 9082224 6430255 4700754 174337293 159100585 4632496 5363509 0 0 70278616 59311958 0 0 0 80576931 78994789 155488043 143670256 18849250 15430329 296538439 321716381 112691951 111219799 183846488 210496582 X SEE SCHEDULE O: 0 0 70800952 5283009 109069704 SEE SCHEDULE O:SCIENTIFIC & MEDICAL EDUCATION:ASCO'S MEETING PORTFOLIO DELIVERS, TO ASCO'S CORE AUDIENCE OF HEALTH PROFESSIONALS, THE SCIENCE AND EDUCATION CRITICAL TO IMPROVING PATIENT CARE AND CLINICAL PRACTICE BY HOSTING CONFERENCES THAT BRING TOGETHER FACULTY AND PRACTITIONERS BOTH IN-PERSON AND ONLINE. IN 2024, ASCO'S PREMIER ANNUAL MEETING, THROUGH OVER 200 SESSIONS, REACHED AN AUDIENCE OF 36,400 PROFESSIONALS, INCLUDING OVER 14,400 PROFESSIONALS FROM 140 NON-US COUNTRIES, BOTH IN-PERSON AND ONLINE. THROUGH ASCO'S ADDITIONAL MEETINGS, THE ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, THE ASCO GENITOURINARY CANCERS SYMPOSIUM, THE ASCO QUALITY CARE SYMPOSIUM, ASCO BREAKTHROUGH, AND THE BEST OF ASCO MEETING, A FURTHER 10,400 PROFESSIONALS, OVER 4,100 OF WHOM WERE OUTSIDE THE UNITED STATES, BENEFITED FROM THE EDUCATION, SCIENCE, AND NETWORKING THAT ASCO PROVIDED. 9374885 0 4963700 SEE SCHEDULE O:RESEARCH INITIATIVES - TAPUR/CENTRA:ASCO'S CENTER FOR RESEARCH AND ANALYTICS "(CENTRA)" LEADS ASCO'S EFFORTS IN RESEARCH AND RELATED TO CLINICAL CANCER RESEARCH. MAJOR PROGRAMS AND PROJECTS INCLUDE: (1) THE TARGETED AGENT AND PROFILING UTILIZATION REGISTRY (TAPUR) STUDY, WHICH IS A PRECISION MEDICINE BASKET TRIAL THAT INVESTIGATES THE EFFICACY OF MORE THAN 15 DIFFERENT ANTI-CANCER TARGETED AGENTS IN PATIENTS WITH ADVANCED CANCERS AND HAS ENROLLED NEARLY 3,000 PATIENTS SINCE IT OPENED IN 2016. TAPUR CONTINUES TO PUBLISH TRIAL RESULTS IN PEER-REVIEWED CLINICAL CANCER RESEARCH JOURNALS AND PRESENT RESULTS AT CLINICAL CANCER RESEARCH CONFERENCES; (2) ASCO'S MEMBER RESEARCH SURVEY POOL, WHICH FACILITATES RESEARCH OF CANCER CARE PROVIDERS BY DISSEMINATING SURVEYS FROM MERITORIOUS SURVEY RESEARCH PROJECTS TO ASCO MEMBERS WHO HAVE AGREED TO BE A PART OF THE SURVEY POOL; (3) THE STATE OF CANCER CARE IN AMERICA PROGRAM, WHICH ASSESSES AND REPORTS ON THE STATE OF AND CHANGES IN CANCER CARE IN THE US; (4) ASCO'S WORK IN IMPROVING ACCESS TO CLINICAL TRIALS THROUGH TRAINING FOR SITES; AND (5) A PATIENT-CENTERED CLINICAL TRIAL, THE CDK4/6 INHIBITOR DOSING STUDY, WHICH OPENED TO ENROLLMENT IN DECEMBER 2024 AND EVALUATES STANDARD VS. TITRATED DOSING APPROACHES FOR PATIENTS AGE 65 AND OLDER WITH HR+/HER2- METASTATIC BREAST CANCER. CENTRA ALSO SUPPORTS WORKSHOPS, MEETINGS, AND RESEARCH PROJECTS WITH OTHER STAKEHOLDERS IN CANCER RESEARCH, INCLUDING THE NCI, THE FDA'S ONCOLOGY CENTER FOR EXCELLENCE, AND OTHER NON-PROFIT GROUPS, SUCH AS THE FRIENDS OF CANCER RESEARCH. 9146436 8000 1452853 SEE SCHEDULE O:QUALITY OF CARE INITIATIVES:QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI) IS A QUALITY SELF-ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICES TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. PRACTICES PARTICIPATE ANNUALLY AND OVER 263 PRATICES PARTICAPTED IN 2024. QUALITY TRAINING PROGRAM. ASCO'S QUALITY TRAINING PROGRAM IS DESIGNED TO EDUCATE AND TRAIN HEMATOLGY-ONOCOLOGY PRACTICE TEAMS ON THE TECHNIQUES OF CLINICAL CARE AND OPERATIONAL PERFORMANCE QUALITY IMPROVEMENT. 290 ONCOLOGY PROFESSIONALS RECEIVED TRAINING IN 2024.GUIDELINES. ASCO'S GUIDELINES PROGRAM ENGAGES WITH MORE THAN 1,000 ASCO MEMBER VOLUNTEERS, ON A YEARLY BASIS, TO DEVELOP EXPERT RECOMMENDATIONS AND STANDARDS DESIGNED TO PROMOTE CONSISTENT, SAFE DELIVERY OF HIGH-QUALITY CANCER CARE WORLDWIDE. CLINICAL CONTENT IS DISSEMINATED USING PUBLISHED ARTICLES, RECOMMENDATION TABLES, ALGORITHMS, PODCASTS, VISUAL ABSTRACTS, AND OTHER RESOURCES ACCESSIBLE THROUGH ASCO JOURNALS, THE ASCO WEBSITE, AND THE ASCO GUIDELINES APP. GUIDELINES ARE AMONG THE MOST READ ARTICLES IN THE JOURNAL OF CLINICAL ONCOLOGY (JCO), WITH OVER 1.1 MILLION DOWNLOADS AND 503 CITATIONS IN 2024. ASCO PUBLISHES BETWEEN 25 AND 30 NEW OR UPDATED GUIDELINES EACH YEAR, WITH A GROWING LIBRARY OF GUIDELINE SUMMARIES THAT HAVE BEEN TRANSLATED INTO SPANISH. A TOTAL OF 39 GUIDELINE PRODUCTS WERE PUBLISHED IN THE JCO FAMILY OF JOURNALS IN 2024, INCLUDING SEVERAL RAPID RECOMMENDATIONS AND MULTIPLE ITERATIONS OF ASCO'S COMPREHENSIVE LIVING GUIDELINE THAT ADDRESSES THE CARE OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER. 20299067 72500 22149676 POLICY:IN COLLABORATION WITH VOLUNTEER EXPERTS, ASCO WORKS TO ADDRESS A WIDE RANGE OF POLICY ISSUES THAT IMPACT THE CANCER CARE DELIVERY SYSTEM AND PEOPLE WITH CANCER. POLICY IS CONVEYED IN FORMAL STATEMENTS PUBLISHED IN ASCO JOURNALS, AND IN PUBLIC FACING COMMUNICATIONS CHANNELS. AREAS OF FOCUS INCLUDE QUALITY AND ACCESS TO CARE, INSURANCE ISSUES, COST, PREVENTION, SURVIVORSHIP, REIMBURSEMENT, AND SUPPORT FOR CLINICAL CANCER RESEARCH. IN 2024, ASCO CONTINUED TO DRAW PUBLIC ATTENTION TO THE PERSISTENT CRISIS OF DRUG SHORTAGES, THE ONGOING AND WORSENING HARMS RELATED TO AGGRESSIVE UTILIZATION MANAGEMENT PRACTICES, THE NEED TO SUSTAIN ACCESS TO EVIDENCE BASED CANCER CARE, THE NEED TO BALANCE BENEFITS/HARMS ASSOCIATED WITH USE OF ARTIFICIAL INTELLIGENCE IN CANCER CARE, AND THE IMPORTANCE OF TELEMEDICINE AS A COMPONENT OF HEALTH CARE DELIVERY.CENTER FOR GLOBAL IMPACT (CGI):ASCO'S INTERNATIONAL AFFAIRS DEPARTMENT HAS TRANSITIONED TO THE CENTER FOR GLOBAL IMPACT (CGI). CGI PARTNERS ACROSS ASCO AND ONCOLOGY COMMUNITIES WORLDWIDE TO INTEGRATE GLOBAL PERSPECTIVES INTO ASCO STRATEGIES AND OPERATIONS, AND TO CATALYZE AND ADVANCE ASCO'S GLOBAL IMPACT GOALS AS DIRECTED BY THE SOCIETY'S MISSION, VISION, AND STRATEGIC PLANS. CGI SERVES AS A RESOURCE ACROSS ASCO FOR GLOBAL ISSUES RELEVANT TO ASCO, WITH A PARTICULAR EMPHASIS ON VOLUNTEER ENGAGEMENT, DIPLOMACY, STRATEGIC PLANNING, PROGRAM DELIVERY, AND GLOBAL OPERATIONS. EXAMPLES OF OPERATIONS ARE AS FOLLOWS:- JOINT SESSIONS- INTERNATIONAL CANCER CORPS- INTERNATIONAL COURSES- INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA)SCIENTIFIC PUBLICATIONS:ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS AND GENERAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. ASCO PUBLISHES HIGH-QUALITY, PEER-REVIEWED SCIENTIFIC PAPERS IN ITS JOURNALS: - JOURNAL OF CLINICAL ONCOLOGY (JCO)- JCO ONCOLOGY PRACTICE (JCO OP)- JCO GLOBAL ONCOLOGY (JCO GO)- JCO CLINICAL CANCER INFORMATICS (JCO CCI)- JCO PRECISION ONCOLOGY (JCO PO)- JCO ONCOLOGY ADVANCES (JCO OA)- ASCO DAILY NEWSASCO ALSO PROVIDES CONTENT AND DISTRIBUTION LISTS FOR TRADE PUBLICATIONS. WHILE NOT OWNED OR PUBLISHED BY ASCO, THE PUBLICATIONS COVER NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY.EDUCATION AND PROFESSIONAL DEVELOPMENT:IN 2024, ASCO LAUNCHED THE INAUGURAL LEADERSHIP DEVELOPMENT PROGRAM (LDP): LATIN AMERICA CLASS OF 12, CREATING A NETWORK OF PHYSICIAN LEADERS TO ADVANCE CANCER CARE. IN 2024, ASCO HAD RECORD VIRTUAL MENTORING PROGRAM PARTICIPATION (68% INCREASE), RESULTING IN THE CREATION OF A TECHNOLOGICAL SOLUTION TO MEET THE DEMAND. THE IN-TRAINING EXAM FOR ONCOLOGY FELLOWS HAD RECORD PARTICIPATION WITH 2333 TRAINEES FROM 20 COUNTRIES ACROSS THE GLOBE PARTICIPATING. ALL PROGRAMS SERVE THE PURPOSE OF BUILDING THE WORKFORCE. 20299067 72500 22149676 109621340 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 1 1 1 0 0 0 0 0 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 1 1 1 1 1 0 1 561 0 1 488 1 1 1 0 0 0 0 0 0 0 0 0 1 0 X 18 18 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 CA NY VA X MELINDA O'LEARY CFO 5714831300 2318 MILL ROAD SUITE 800 ALEXANDRIA VA 22314 EVERETT E VOKES MD PAST PRESIDENT (PARTIAL YEAR) 1.00 1.00 X X 0 0 0 ERIC P WINER MD CHAIR/PAST PRESIDENT 1.00 1.00 X X 0 0 0 LYNN M SCHUCHTER MD PRESIDENT/CHAIR 1.00 1.00 X X 0 0 0 ROBIN ZON MD PRESIDENT-ELECT/PRESIDENT 1.00 1.00 X X 0 0 0 ERIC J SMALL MD PRESIDENT-ELECT(PARTIAL YEAR) 1.00 1.00 X X 0 0 0 ELIZABETH R PLIMACK MD MS TREASURER (PARTIAL YEAR) 1.00 1.00 X X 0 0 0 TAOFEEK K OWONIKOKO MD PHD TREASURER-ELECT/TREASURER 1.00 1.00 X X 0 0 0 CAROLYN B HENDRICKS MD TREASURER-ELECT (PARTIAL YEAR) 1.00 1.00 X X 0 0 0 FREDRICK CHITE ASIRWA MD MBCHB BOARD MEMBER 1.00 X 0 0 0 LISA A CAREY MD BOARD MEMBER (PARTIAL YEAR) 1.00 1.00 X 0 0 0 MARIANA CHAVEZ MACGREGOR MD MSC BOARD MEMBER 1.00 1.00 X 0 0 0 TONI K CHOUEIRI MD BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 JHANELLE E GRAY MD BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 TARA O HENDERSON MD MPH BOARD MEMBER (PARTIAL YEAR) 1.00 1.00 X 0 0 0 CLARISSA MATHIAS MD PHD BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 KATHLEEN N MOORE MD MS BOARD MEMBER 1.00 X 0 0 0 ANN H PARTRIDGE MD MPH BOARD MEMBER 1.00 X 0 0 0 DEBRA A PATT MD PHD BOARD MEMBER 1.00 X 0 0 0 GLADYS I RODRIGUEZ MD BOARD MEMBER 1.00 1.00 X 0 0 0 ABBY R ROSENBERG MD BOARD MEMBER (PARTIAL YEAR) 1.00 X 0 0 0 ENRIQUE SOTO PEREZ DE CELIS MD MSC BOARD MEMBER (PARTIAL YEAR) 1.00 1.00 X 0 0 0 JENNIFER TEMEL MD BOARD MEMBER 1.00 X 0 0 0 KAREN M WINKFIELD MD PHD BOARD MEMBER 1.00 X 0 0 0 CLIFFORD A HUDIS MD CEO 30.00 7.50 X 1114041 0 25875 DINA MICHELS ESQ SECRETARY, EVP & COO 37.50 X 710762 0 47358 MELINDA O'LEARY CFO (PARTIAL YEAR) 30.00 7.50 X 259970 0 24887 JULIE R GRALOW MD EVP & CMO 37.50 X 657910 0 47358 CHRISTOPHER MERLAN EVP & CHIEF DIGITAL OFFICER 37.50 X 495256 0 50013 NANCY DALY MS MPH EVP & CONQUER CANCER CEO 1.00 36.50 X 536218 0 47217 JAMIE VON ROENN MD VP, EDU. (PARTIAL YEAR) 37.50 X 253146 0 27866 BARTON LAWYER VICE PRESIDENT - IT 37.50 X 316766 0 53205 AMANDA DAVIS-AITKEN VICE PRESIDENT, MEETING SERVICES 37.50 X 351635 0 36612 ANGELA COCHRAN VP, PUBLISHING 37.50 X 351613 0 44703 JULIA CLOSE MD EVP & CHIEF ED. OFFICER (PARTIAL YR) 37.50 X 183601 0 20070 MELISSA TAI ESQ VP, CEIL & GENERAL COUNSEL 29.50 8.00 X 369986 0 55293 STEPHEN GRUBBS MD VP, CARE DELIVERY 37.50 X 459466 0 46603 PAULA KING CHIEF HUMAN RESOURCES OFFICER 37.50 X 379435 0 50013 DEBORAH KAMIN PHD VP, POLICY/ADVOCACY 37.50 X 389727 0 47217 KRISTEN NEESE CHIEF MARKETING & COMMUNICATIONS OFFICER 37.50 X 387841 0 50013 CARMEN JACKSON CLQ CEO 0.00 X 511604 0 0 7728977 0 674303 232 1 1 0 FREEMAN PO BOX 734596 DALLAS TX 753734596 EVENT MANAGEMENT 11417085 SPARGO INC 11208 WAPLES MILL ROAD 122 FAIRFAX VA 22030 EVENT MANAGEMENT 4907693 BRILLIO LLC 399 THORNALL ST 1ST FL EDISON NJ 08837 IT SERVICES 2848936 KUSHNER & ASSOCIATES 4500 PARK GRANADA STE 202 CALABASAS CA 91302 TRANSPORTATION 1951549 SMG FOOD & BEVERAGE LLC 747 HOWARD ST SAN FRANCISCO CA 94103 CATERING 1918172 92 7681674 7681674 EDUCATIONAL MTGS & FEE 900099 109576639 101322640 8253999 SCIENTIFIC PUBLICATION 513120 21752294 15825628 5926666 RESEARCH 900099 6259000 6259000 QUALITY OF CARE 900099 48000 48000 137635933 6500534 6500534 1882508 1882508 4144805 1414547 2730258 2730258 2730258 18953233 302722 16674265 0 2278968 302722 2581690 2581690 MISC INCOME 900099 67214 67214 VISITOR PARKING 812930 20774 20774 87988 159100585 123455268 14268653 13694990 X 5333240 5333240 18250 18250 12019 12019 5964017 4213878 1750139 40929791 28931351 11998440 3127545 2192761 934784 5970312 4212699 1757613 3320293 2329170 991123 288854 287672 1182 174258 174258 130739 130739 22900492 17565671 5334821 1042816 1038549 4267 6193762 5409398 784364 6023766 1471230 4552536 3410473 1967053 1443420 5970686 4490812 1479874 22721503 22721503 1109958 498730 611228 5065126 3456352 1608774 1230873 950484 280389 UBI TAX 1771064 1718886 52178 CLINICAL SITE PAYMENTS 769000 769000 BAD DEBT 103831 103831 87588 32632 54956 143670256 109621340 34048916 0 9395785 6471398 12675262 31168008 8339401 5675802 107256313 42406016 53189639 64850297 208311312 210045111 4627040 3505765 296538439 321716381 11247077 14760833 52717228 52537124 43521229 40538859 5206417 3382983 112691951 111219799 X 183557748 210386731 288740 109851 183846488 210496582 296538439 321716381 15430329 11219765 0 X 0 1 X 1 1 1 X 6446971 7826511 9250760 16259283 7681674 47465199 98737324 80888354 108839499 114290944 123455268 526211389 105184295 88714865 118090259 130550227 131136942 573676588 75000 75000 0 75000 75000 573601588 18248056 15214892 15080053 12212849 12527847 73283697 18248056 15214892 15080053 12212849 12527847 73283697 8302393 7677032 8115539 6952857 7667167 38714988 131734744 111606789 141285851 149715933 151331956 685675273 0.83650 0.84080 0.10690 0.10180 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 143670256 143670256 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 250000 250000 250000 250000 1000000 1500000 69661582 19596869 50064713 763557 761028 2529 13226682 9097770 4128912 23604492 12950349 10654143 64850297 DEFERRED COMPENSATION LIABILITY 3349637 OPERATING LEASE OBLIGATION 33346 3382983 X PART X, LINE 2: THE ORGANIZATION ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES IN ACCORDANCE WITH THE INCOME TAX TOPIC OF THE FINANCIAL ACCOUNTING STANDARDS BOARD ACCOUNTING STANDARDS CODIFICATION ("FASB ASC"). THE ORGANIZATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN AND, AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE CONSOLIDATED FINANCIAL STATEMENTS. GENERALLY, THE ORGANIZATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS BEFORE 2021. 1 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 5 PROGRAM SERVICES QUALITY OF CARE 741456 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 2716339 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 53578 SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 13716 SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 47153 SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 27594 RUSSIA AND NEIGHBORING STATES - ARMENIA, AZERBIJAN, BELARUS, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 1000 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 0 PROGRAM SERVICES OUTREACH & EDUCATION 750 0 5 0 0 0 5 3601586 0 3601586 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM WORLD CANCER LEADER'S SUMMIT 11019 0 1 0 0 0 0 0 0 1 PART I, LINE 2: ASCO PROVIDED HONORARIA AND EXPENSE REIMBURSEMENTS TO MEETING SPEAKERS AND PRESENTERS. HONORARIA AND EXPENSE REIMBURSEMENTS WERE PAID DIRECTLY TO THE PRESENTERS. PART I, LINE 3: THE ACCRUAL METHOD WAS USED TO ACCOUNT FOR EXPENDITURES IN RELATION TO FOREIGN PROGRAM SERVICES. 1 BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 506 S WRIGHT ST URBANA IL 61801 376000511 STATE OF IL 84872 0 CLINICAL INVESTIGATOR LEADERSHIP AWARD CANCERCARE 275 SEVENTH AVENUE 22ND FL NEW YORK NY 10001 131825919 501(C)(3) 15000 0 CONTRIBUTION CINCINNATI CANCER FOUNDATION INC PO BOX 8280 CINCINNATI OH 45208 814093626 501(C)(3) 152500 0 CONTRIBUTION CONQUER CANCER FOUNDATION OF ASCO 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 311667995 501(C)(3) 3770000 0 CONTRIBUTION ECOG-ACRIN MEDICAL RESEARCH FOUNDATION 1818 MARKET STREET SUITE 3000 PHILADELPHIA PA 19103 460745339 501(C)(3) 40000 0 CLINICAL INVESTIGATOR LEADERSHIP AWARD FOX CHASE CANCER CENTER 3509 N BROAD ST RM 936 PHILADELPHIA PA 19140 231352156 501(C)(3) 30000 0 CONTRIBUTION HEALTH VOLUNTEERS OVERSEAS 1900 L STREET NW STE 310 WASHINGTON DC 20036 521485477 501(C)(3) 10000 0 VOLUNTEER ONCOLOGY SITES JOHNS HOPKINS UNIVERSITY 3910 KESWICK ROAD SUITE N2100 BALTIMORE MD 21211 520595110 501(C)(3) 84872 0 CONTRIBUTION MAYO CLINIC JACKSONVILLE PO BOX 860334 MINNEAPOLIS MN 554860334 593337028 501(C)(3) 84872 0 CONTRIBUTION MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE NEW YORK NY 10065 131924236 501(C)(3) 84872 0 CONTRIBUTION THE CHILDREN'S ONCOLOGY GROUP FOUNDATION 40 WEST EVERGREEN AVE SUITE 101 PHILADELPHIA PA 19118 453083156 501(C)(3) 40000 0 CLINICAL INVESTIGATOR LEADERSHIP AWARD UNIVERSITY OF CALIFORNIA SAN FRANCISCO PO BOX 0962 490 ILLINOIS ST 4TH FL SAN FRANCISCO CA 94143 943067788 501(C)(3) 169872 0 CONTRIBUTION UNIVERSITY OF CHICAGO 5801 ELLIS AVE CHICAGO IL 60637 362177139 501(C)(3) 30000 0 CONTRIBUTION UNIVERSITY OF FLORIDA PO BOX 14425 GAINSEVILLE FL 32604 590974739 501(C)(3) 84872 0 CONTRIBUTION UNIVERSITY OF MARYLAND 4101 CHESAPEAKE BLDG 3200 TERRAPIN TRAIL COLLEGE PARK MD 20742 526002033 STATE OF MD 75000 0 CONTRIBUTION UNIVERSITY OF PENNSYLVANIA 3451 WALNUT ST RM 305 PHILADELPHIA PA 19104 231352685 501(C)(3) 195000 0 CANCER RESEARCH & EDUCATION UNIVERSITY OF TEXAS 2200 SAN ANTONIO ST AUSTIN TX 78705 270426799 501(C)(3) 84872 0 CONTRIBUTION VANDERBILT UNIVERSITY MEDICAL CENTER 1211 MEDICAL CENTER DRIVE NASHVILLE TN 37232 352528741 501(C)(3) 84872 0 CLINICAL INVESTIGATOR LEADERSHIP AWARD YALE UNIVERSITY PO BOX 208239 NEW HAVEN CT 06520 060646973 501(C)(3) 95250 0 CONTRIBUTION 19 0 ANNUAL MEETING AWARDS 13 18250 PART I, LINE 2: ASCO PROVIDES ASSISTANCE TO ORGANIZATIONS THAT SERVE THE CANCER CARE COMMUNITY. THE MAJORITY OF THESE GRANTS ARE MADE TO OTHER 501(C)(3) ORGANIZATIONS. GRANTS MADE TO NON-501(C)(3) ORGANIZATIONS ARE MADE PURSUANT TO A WRITTEN AGREEMENT THAT REQUIRED THE GRANT FUNDS TO BE USED FOR SPECIFIC EDUCATIONAL AND CHARITABLE PROJECTS, THAT THE GRANTEE RETURN ANY PORTION OF THE GRANT FUNDS THAT WERE NOT USED FOR SUCH PROJECTS, AND THAT THE GRANTEE PROVIDE ANNUAL NARRATIVE AND FINANCIAL REPORTS TO ASCO REGARDING GRANTEE'S USE OF THE GRANT FUNDS. X X X X X 1 0 0 0 0 0 0 1 0 CLIFFORD A HUDIS MD CEO 1101755 0 10000 0 2286 0 25875 0 0 0 1139916 0 0 0 DINA MICHELS ESQ SECRETARY, EVP & COO 667574 0 42000 0 1188 0 25875 0 21483 0 758120 0 0 0 JULIE R GRALOW MD EVP & CMO 645624 0 10000 0 2286 0 25875 0 21483 0 705268 0 0 0 NANCY DALY MS MPH EVP & CONQUER CANCER CEO 522932 0 11000 0 2286 0 25875 0 21342 0 583435 0 0 0 CHRISTOPHER MERLAN EVP & CHIEF DIGITAL OFFICER 484282 0 10200 0 774 0 25875 0 24138 0 545269 0 0 0 CARMEN JACKSON CLQ CEO 511604 0 0 0 0 0 0 0 0 0 511604 0 0 0 STEPHEN GRUBBS MD VP, CARE DELIVERY 445758 0 10000 0 3708 0 25875 0 20728 0 506069 0 0 0 KRISTEN NEESE CHIEF MARKETING & COMMUNICATIONS OFF 375427 0 12000 0 414 0 25875 0 24138 0 437854 0 0 0 DEBORAH KAMIN PHD VP, POLICY/ADVOCACY 376019 0 10000 0 3708 0 25875 0 21342 0 436944 0 0 0 PAULA KING CHIEF HUMAN RESOURCES OFFICER 366047 0 12200 0 1188 0 25875 0 24138 0 429448 0 0 0 MELISSA TAI ESQ VP, CEIL & GENERAL COUNSEL 357716 0 12000 0 270 0 25875 0 29418 0 425279 0 0 0 ANGELA COCHRAN VP, PUBLISHING 341199 0 10000 0 414 0 25875 0 18828 0 396316 0 0 0 AMANDA DAVIS-AITKEN VICE PRESIDENT, MEETING SERVICES 341365 0 10000 0 270 0 25875 0 10737 0 388247 0 0 0 BARTON LAWYER VICE PRESIDENT - IT 306352 0 10000 0 414 0 23625 0 29580 0 369971 0 0 0 MELINDA O'LEARY CFO (PARTIAL YEAR) 259731 0 0 0 239 0 19616 0 5271 0 284857 0 0 0 JAMIE VON ROENN MD VP, EDU. (PARTIAL YEAR) 238303 0 12989 0 1854 0 17524 0 10342 0 281012 0 0 0 JULIA CLOSE MD EVP & CHIEF ED. OFFICER (PARTIAL YR) 183518 0 0 0 83 0 12382 0 7688 0 203671 0 0 0 PART I, LINE 4A CARMEN JACKSON RECEIVED SEVERANCE IN THE AMOUNT OF $511,604 IN 2024. PART I, LINE 7 THE ORGANIZATION HAS A DISCRETIONARY BONUS PLAN UNDER WHICH SELECTED EMPLOYEES, INCLUDING OFFICERS, KEY EMPLOYEES, AND OTHER EMPLOYEES ARE COMPENSATED BASED ON PERFORMANCE AND THE ACHIEVEMENT OF ORGANIZATIONAL GOALS. BONUSES FOR KEY EMPLOYEES AND HIGHEST COMPENSATED EMPLOYEES ARE APPROVED BY THE CHIEF EXECUTIVE OFFICER WITH REVIEW AND APPROVAL BY THE COMPENSATION COMMITTEE OF THE BOARD, WHERE APPROPRIATE. BONUSES FOR THE CHIEF EXECUTIVE OFFICER, IF ANY, ARE REVIEWED BY THE COMPENSATION COMMITTEE AS PART OF THE CHIEF EXECUTIVE OFFICER'S ANNUAL COMPENSATION REVIEW PROCESS, AND APPROVED BY THE BOARD OF DIRECTORS. IN ADDITION, THE ORGANIZATION AWARDS MODEST AMOUNTS TO EMPLOYEES ON ACHIEVING CERTAIN NUMBER OF YEARS OF EMPLOYMENT. FROM TIME TO TIME, THE ORGANIZATION MAY MAKE STANDARD PAYMENTS TO ITS EMPLOYEES IN GOOD STANDING WITH MINIMUM TIME OF EMPLOYMENT TO RECOGNIZE EFFORT AND COMMITMENT TO THE ORGANIZATION'S GOALS IN THAT YEAR. LORI PIERCE MD FORMER BOARD & OFFICER 5000 AWARD SEE PART V (E) PURPOSE OF ASSISTANCE: EACH YEAR, THE SOCIETY RECOGNIZES RESEARCHERS, PATIENT ADVOCATES, TEACHERS, AND GLOBAL ONCOLOGY LEADERS WHO HAVE RESHAPED CANCER CARE AROUND THE WORLD THROUGH ITS HIGHEST HONORS, THE ASCO SPECIAL AWARDS. ASCO SPECIAL AWARDS HONOR THE ACHIEVEMENTS OF INDIVIDUALS WHO HAVE MADE NOTEWORTHY CONTRIBUTIONS TO THE FIELD OF ONCOLOGY, SUCH AS THOSE WHO HAVE DEMONSTRATED INNOVATIVE AND INSPIRATIONAL LEADERSHIP BY PROMOTING THE HIGHEST QUALITY PATIENT CARE AND IMPROVING THE LIVES OF PATIENTS WITH CANCER; WHO HAVE DEMONSTRATED OUTSTANDING LEADERSHIP AND ACHIEVEMENT IN SPECIFIC ONCOLOGY SPECIALTIES SUCH AS GERIATRIC ONCOLOGY AND BREAST CANCER; AND WHO HAVE MADE A DEMONSTRABLE IMPACT THROUGH TEACHING, TRAINING, AND MENTORING ONCOLOGISTS AND CARE TEAM MEMBERS. CANDIDATES FOR ASCO SPECIAL AWARDS ARE NOMINATED BY THE ASCO MEMBERSHIP USING AN ONLINE PORTAL. NOMINATIONS ARE REVIEWED BY A SELECTION COMMITTEE, WHOSE MEMBERS ARE CHOSEN FOR THEIR EXPERTISE AND KNOWLEDGE IN THE SUBJECT AREAS OF THE SPECIAL AWARD CATEGORIES ACROSS THE BREADTH OF CANCER MEDICINE. SPECIAL AWARD SELECTION COMMITTEE MEMBERS MUST DISCLOSE POTENTIAL CONFLICTS OF INTEREST AND COMPLY WITH THE SOCIETY'S CONFLICT OF INTEREST POLICIES. CURRENT SOCIETY BOARD MEMBERS AND OFFICERS ARE NOT ELIGIBLE TO RECEIVE ASCO SPECIAL AWARDS.THE SLATE OF RECOMMENDED SPECIAL AWARD RECIPIENTS, AS DETERMINED BY THE SPECIAL AWARD SELECTION COMMITTEE, IS SUBMITTED FOR FINAL APPROVAL BY THE SOCIETY'S BOARD OF DIRECTORS.THROUGH THIS PROCESS, DR. LORI PIERCE WAS AWARDED AN ASCO SPECIAL AWARD IN 2024. THE AWARD CONSISTED OF A $5,000 HONORARIUM AND COMMEMORATIVE PLAQUE. DR. PIERCE'S TERM ON THE SOCIETY'S BOARD OF DIRECTORS, AND AS THE SOCIETY'S PAST PRESIDENT, ENDED IN JUNE OF 2023. FORM 990, PART VI, SECTION A, LINE 1A AS OF DECEMBER 31, 2024, THE BOARD OF DIRECTORS OF ASCO INCLUDED 18 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDED TWO EX-OFFICIO DIRECTORS WITHOUT THE RIGHT TO VOTE, WHO WERE THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO) AND THE CHAIR OF THE BOARD OF DIRECTORS OF ASCO'S RELATED 501(C)(3) ORGANIZATION, THE CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. PURSUANT TO THE BYLAWS, THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE ARE THE PRESIDENT, THE PRESIDENT-ELECT, THE CHAIR, THE PAST PRESIDENT, THE TREASURER, THE TREASURER-ELECT, AND THOSE DIRECTORS SERVING THE FINAL YEAR OF THEIR PRESENT TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS, AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED MEETING OF THE BOARD OF DIRECTORS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. FORM 990, PART VI, SECTION A, LINE 6 ALL ASCO MEMBERS MUST BE ONCOLOGY MEDICAL PROFESSIONALS, DEFINED AS INDIVIDUALS WHO MEET ANY OF THE FOLLOWING QUALIFICATIONS: (1) INDIVIDUALS WHOSE PROFESSIONAL CREDENTIALS AND ACTIVITIES INVOLVE CANCER PATIENT CARE AND/OR RESEARCH, EDUCATION, OR ADVOCACY IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER; (2) INDIVIDUALS WHO ARE RETIRED FROM PROFESSIONAL ACTIVITIES, BUT WHOSE PROFESSIONAL ACTIVITIES PRIOR TO RETIREMENT INCLUDED THOSE SET FORTH ABOVE; (3) INDIVIDUALS WHO ARE STUDENTS TRAINING TO BE PROFESSIONALS DESCRIBED ABOVE. VOTING MEMBERS ARE ONCOLOGY MEDICAL PROFESSIONALS WHO HAVE BEEN AWARDED AND HOLD THE DEGREE OF DOCTOR OF MEDICINE, DOCTOR OF OSTEOPATHY, DOCTOR OF PHILOSOPHY, DOCTOR OF PHARMACY, DOCTOR OF MEDICAL SCIENCE, DOCTOR OF NURSING SCIENCE, DOCTOR OF NURSING PRACTICE, OR EQUIVALENT DOCTORAL-LEVEL DEGREE AS DETERMINED FROM TIME TO TIME BY ASCO AND THE ASSOCIATION. ONLY VOTING MEMBERS ARE ELIGIBLE TO VOTE OR SERVE ON THE BOARD OF DIRECTORS, ON THE NOMINATING COMMITTEE, OR AS ELECTED OFFICERS. FORM 990, PART VI, SECTION A, LINE 7A VOTING MEMBERS OF ASCO ELECT ALL VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7B ASCO'S CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED, AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. FORM 990, PART VI, SECTION B, LINE 11B AN ELECTRONIC COPY OF THE FINAL FORM WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS, AND WAS REVIEWED BY THE VICE PRESIDENT & CHIEF FINANCIAL OFFICER; THE CHIEF EXECUTIVE OFFICER; AND THE EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER & CHIEF LEGAL OFFICER PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICTS OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND CERTAIN FAMILY MEMBERS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER AND WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION-MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERNATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE EXECUTIVE VICE CHAIR OF ASCO'S NON-PROFIT, 501(C)(3) TAX- EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CC); THE CEO OF ASCO'S NON-PROFIT, 501(C)(6) TAX-EXEMPT RELATED ORGANIZATION, ASCO ASSOCIATION (D/B/A ASSOCIATION FOR CLINICAL ONCOLOGY)(ASSOCIATION), THE PRESIDENT OF QOPI CERTIFICATION PROGRAM, LLC; AND THE PRESIDENT OF ASCO LEASING LLC. ALL ORGANIZATIONS LISTED ARE RELATED ORGANIZATIONS OF ASCO. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2024. THE COMPENSATION OF THE FOLLOWING POSITIONS WAS CONSIDERED AND APPROVED BY THE ASCO BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND AN INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA (INCLUDING DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS) AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR EACH OF THE POSITIONS WAS REASONABLE. - EXECUTIVE VICE PRESIDENT & CHIEF OPERATING OFFICER & CHIEF LEGAL OFFICER & ASCO SECRETARY (EVP & COO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & COO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2024. THE EVP & COO'S COMPENSATION WAS ALSO REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, AS REQUIRED UNDER STATE LAW. - EXECUTIVE VICE PRESIDENT & CHIEF MEDICAL OFFICER (EVP & CMO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CMO BASED ON THE ABOVE-DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2024. - EXECUTIVE VICE PRESIDENT & CHIEF DIGITAL OFFICER (EVP & CDO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CDO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2024. - EXECUTIVE VICE PRESIDENT OF ASCO & CHIEF EXECUTIVE OFFICER OF THE CONQUER CANCER FOUNDATION OF ASCO (EVP & CC CEO): THE EVP & CC CEO IS AN EMPLOYEE OF ASCO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CC CEO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2024. - EXECUTIVE VICE PRESIDENT & CHIEF EDUCATION OFFICER (EVP & CEDO): THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CEDO BASED ON THE ABOVE-DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2024. FORM 990, PART VI, SECTION C, LINE 18 ASCO'S FORM 1023, 990 AND 990-T ARE MADE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 17,565,671. MANAGEMENT AND GENERAL EXPENSES 5,334,821. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 22,900,492. ASCO LEASING LLC 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 273378225 RENTAL VA 3152616 17096114 ASCO CONQUER CANCER FOUNDATION OF ASCO 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 311667995 GRANTMAKING VA 501(C)(3) LINE 7 ASCO 1 ASCO ASSOCIATION 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 833561693 PROMOTING COMMON INTERESTS OF MEMBERS VA 501(C)(6) ASCO 1 ASCO ASSOCIATION POLITICAL ACTION COMM 2318 MILL RD SUITE 800 ALEXANDRIA VA 22314 844213157 ADVOCACY VA 527 ASCO ASSOC 0 0 1 1 0 0 0 0 0 0 1 0 1 1 1 1 1 1 0 0 CONQUER CANCER FOUNDATION OF ASCO B 3770000 FMV CONQUER CANCER FOUNDATION OF ASCO C 7681670 FMV ASCO ASSOCIATION N 521448 FMV CONQUER CANCER FOUNDATION OF ASCO N 168040 FMV ASCO ASSOCIATION Q 349015 FMV CONQUER CANCER FOUNDATION OF ASCO Q 11226888 FMV